Switzerland

On January 13, 2026, UBS Group AG successfully completed its issuance of EUR 1.5 bn in aggregate principal amount of Fixed Rate/Fixed Rate Callable Senior Notes due February 2031 and EUR 1.5 bn in aggregate principal amount of Fixed Rate/Fixed Rate Callable Senior Notes due January 2037 under its Senior Debt Programme. The Notes are bail-inable (TLAC) bonds that are eligible to count towards UBS Group AG’s Swiss gone concern capital requirement. The Notes are governed by Swiss law, and the Notes have been provisionally admitted to trading, and application will be made for definitive admission to trading and listing of the Notes, on the SIX Swiss Exchange. The Homburger team was led by Stefan Kramer and Benedikt Maurenbrecher (both Capital Markets) and included Lee Saladino, Olivier Baum and Daniel Hulmann (all Capital Markets) as well as Stefan Oesterhelt (Tax). Contact Wanda Schweda / Marketing / [email protected]

On January 13, 2026, Baseline Wealth Management, an established FINMA-registered portfolio manager and SEC-registered investment advisor (RIA) with offices in Geneva and Zurich, announced it has joined Creative Planning, one of the largest RIAs in the United States. The transaction represents Creative Planning’s first international acquisition and underscores the attractivity of Baseline's experience serving international and U.S. clients. The acquisition adds more than USD 1 bn in assets under management to Creative Planning. The Homburger team was led by Frank Gerhard (Corporate / M&A) and included Romain Hondius, Thomas Romelli and Constantin Khovrin (all Corporate / M&A), Alexander Wherlock (Financial Market Regulation) and Philippe Weber (Tax).   Contact Gloria Pünchera / Marketing / [email protected]  

Nxera Pharma Co. Ltd, listed on the Tokio Stock Exchange, has entered into an exclusive licensing agreement with Santhera Pharmaceuticals under which Nxera will commercialize the drug AGAMREE® in Japan, South Korea, Australia and New Zealand. Concurrently, Nxera invests in SIX-listed Santhera Pharmaceuticals Holding AG. Bär & Karrer acted as legal advisor to Nxera Pharma regarding the investment and Swiss law aspects of the license. The team was co-led by Luca Jagmetti (M&A) and Urs Kägi (Capital Markets) and included Oliver Brupbacher (Life Science), Markus Wang (IP), Matthias Tanner (Capital Markets) and Sebastian Sutter (M&A).

In connection with a carve-out process, the Ortlinghaus Group sold its EM+H Division, which encompasses among others the production and sale of electromagnetic brakes and clutches as well as pneumatic toothed clutches and other trade goods to Stüwe Switzerland AG, a group company of Stüwe GmbH &Co. KG. The transaction has already been completed. Bär & Karrer acts as legal advisor to the Ortlinghaus Group in this carve-out process. The team of Bär & Karrer is co-led by Christoph Neeracher and Philippe Seiler and includes Li Wei Dutler and Markus Mezger (both M&A), Rocco Rigozzi and Corina Moschen (both Real Estate), Laura Widmer (Employment), Raoul Stocker and Fabian Capt (both Tax) Markus Wang and Christine Schweikard (both IP/IT) as well as Ruth Bloch-Riemer (Social Security).